Lawrence Fong, M.D., Clinical Team Leader University of California, San Francisco

Today’s new immunotherapies are changing the paradigm for how we treat patients with cancer.
Area of Research: Brain Cancer, Colorectal Cancer, Prostate Cancer, All Cancers

Dr. Fong, along with Hideho Okada, M.D., Ph.D., Kunle Odunsi, M.D., Ph.D., and Pawel Kalinski, M.D., Ph.D., is focusing on timely development of innovative clinical strategies to improve the ability of T cells to infiltrate and eliminate tumors. Although technologies are available for systemic infusion of large numbers of anti-cancer T cells and reversal of local immune suppression for solid cancers including brain, colorectal, ovarian and prostate, a major unsolved challenge is to drive sufficient number of T cells to the tumor site. To address this, Dr. Fong and his colleagues are testing a triple combination called CKM―of IFN-α, TLR3 ligands (PolyI:PolyC12U/rintatolimod or Poly-ICLC) and celecoxib―in preclinical cancer models as well as in phase I and II clinical trials. They're also evaluating how the CKM regimen combines with vaccines and checkpoint immunotherapy.

Projects and Grants

Enhancing T-cell homing to solid cancers by stimulating proper chemokines

University of California, San Francisco | All Cancers, Brain Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer | 2015

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.